CN110662763A - Nav1.9的靶点多肽、与其结合的抗体及抗体片段和相关药物组合物 - Google Patents
Nav1.9的靶点多肽、与其结合的抗体及抗体片段和相关药物组合物 Download PDFInfo
- Publication number
- CN110662763A CN110662763A CN201880024589.5A CN201880024589A CN110662763A CN 110662763 A CN110662763 A CN 110662763A CN 201880024589 A CN201880024589 A CN 201880024589A CN 110662763 A CN110662763 A CN 110662763A
- Authority
- CN
- China
- Prior art keywords
- antibody
- antibody fragment
- seq
- fragment
- voltage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供了一种靶向细胞膜电压门控钠离子通道α亚基Nav1.9的抗体或其抗体片段，其特异结合的靶点为电压门控钠离子通道α亚基的第II结构域的电压传感器桨的S3‑4环。所述抗体或其抗体片段能失活电压传感器阀门，使得钠离子不能正常进入神经细胞，从而达到治疗和缓解疼痛的效果。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017100932902 | 2017-02-21 | ||
| CN201710093290 | 2017-02-21 | ||
| PCT/CN2018/075603 WO2018153262A1 (zh) | 2017-02-21 | 2018-02-07 | Nav1.9的靶点多肽、与其结合的抗体及抗体片段和相关药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110662763A true CN110662763A (zh) | 2020-01-07 |
| CN110662763B CN110662763B (zh) | 2021-06-18 |
Family
ID=63252379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880024589.5A Active CN110662763B (zh) | 2017-02-21 | 2018-02-07 | Nav1.9的靶点多肽、与其结合的抗体及抗体片段和相关药物组合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11136382B2 (zh) |
| EP (1) | EP3594234A4 (zh) |
| CN (1) | CN110662763B (zh) |
| CA (1) | CA3062486A1 (zh) |
| WO (1) | WO2018153262A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113527479A (zh) * | 2020-04-17 | 2021-10-22 | 易森荟(武汉)生物医药有限公司 | 特异结合电压门控钠离子通道α亚基Nav1．7的抗体或抗体片段 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114805497B (zh) * | 2021-01-29 | 2023-09-22 | 李威 | 一种靶向钠离子通道蛋白Nav1.4的新型多肽NaV-B及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102597002A (zh) * | 2009-10-27 | 2012-07-18 | Ucb医药有限公司 | 离子通道的抗体 |
| WO2014207402A1 (fr) * | 2013-06-28 | 2014-12-31 | Galderma Research & Development | Anticorps dirigés contre le canal sodique nav1.9 humain et leurs utilisations en diagnostic |
| US9139648B1 (en) * | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| WO2016071701A1 (en) * | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
-
2018
- 2018-02-07 CA CA3062486A patent/CA3062486A1/en active Pending
- 2018-02-07 CN CN201880024589.5A patent/CN110662763B/zh active Active
- 2018-02-07 WO PCT/CN2018/075603 patent/WO2018153262A1/zh unknown
- 2018-02-07 EP EP18758448.7A patent/EP3594234A4/en active Pending
-
2019
- 2019-10-18 US US16/657,515 patent/US11136382B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102597002A (zh) * | 2009-10-27 | 2012-07-18 | Ucb医药有限公司 | 离子通道的抗体 |
| WO2014207402A1 (fr) * | 2013-06-28 | 2014-12-31 | Galderma Research & Development | Anticorps dirigés contre le canal sodique nav1.9 humain et leurs utilisations en diagnostic |
| US9139648B1 (en) * | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| WO2016071701A1 (en) * | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113527479A (zh) * | 2020-04-17 | 2021-10-22 | 易森荟(武汉)生物医药有限公司 | 特异结合电压门控钠离子通道α亚基Nav1．7的抗体或抗体片段 |
| CN113527479B (zh) * | 2020-04-17 | 2022-05-31 | 易森荟(武汉)生物医药有限公司 | 特异结合电压门控钠离子通道α亚基Nav1.7的抗体或抗体片段 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110662763B (zh) | 2021-06-18 |
| US11136382B2 (en) | 2021-10-05 |
| CA3062486A1 (en) | 2019-11-26 |
| EP3594234A4 (en) | 2021-01-20 |
| EP3594234A1 (en) | 2020-01-15 |
| US20200157198A1 (en) | 2020-05-21 |
| WO2018153262A1 (zh) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9556268B2 (en) | Therapeutic agent | |
| CN109206514B (zh) | Tslp单克隆抗体及其制备方法和应用 | |
| KR20190098976A (ko) | 타우 응집을 방지하기 위한 모노클로날 항-알파-시누클레인 항체 | |
| CN111378043B (zh) | 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用 | |
| US11174312B2 (en) | Nav1.9 target polypeptide, antibody and antibody fragment combined with same, and related pharmaceutical composition | |
| US20210070875A1 (en) | Anti-c5ar antibody and preparation method and use thereof | |
| CN113416245A (zh) | 一种可结合SARS-CoV-2病毒RBD蛋白的中和抗体及其应用 | |
| CN110662763B (zh) | Nav1.9的靶点多肽、与其结合的抗体及抗体片段和相关药物组合物 | |
| EP3209686B1 (en) | Monoclonal anti-gpc-1 antibodies and uses thereof | |
| CN115443150A (zh) | 新型ddr1抗体和其用途 | |
| US20230399384A1 (en) | Antibodies to coronavirus spike protein and methods of use thereof | |
| US9951135B2 (en) | Monoclonal antibodies against the DEC-205 receptor of chicken dendritic cells | |
| CN116003611B (zh) | 抗tmprss2抗体及其用途 | |
| CN113527479B (zh) | 特异结合电压门控钠离子通道α亚基Nav1.7的抗体或抗体片段 | |
| WO2007023782A1 (ja) | キラートキシン様タンパク質に対する中和抗体、およびその利用 | |
| CN113480646B (zh) | 特异性结合h1.4移码突变蛋白的单克隆抗体制备及其应用 | |
| CN107074925A (zh) | 用于预防和/或治疗亨廷顿氏病的物质和方法 | |
| CN117003863A (zh) | 针对p-tau 217的抗体及其用途 | |
| JPH11235186A (ja) | 神経組織のナトリウムチャンネルをコードする核酸 | |
| WO2022241752A1 (zh) | 特异结合电压门控钠离子通道α亚基Nav1.7的抗体或抗体片段 | |
| CN101838650B (zh) | 人类新基因famlf在人基因重组、恶性肿瘤基因检测、特异性单克隆抗体的研制与应用 | |
| JP6434736B2 (ja) | Ａｍｐａ型グルタミン酸受容体サブユニットを認識するモノクローナル抗体及びその利用 | |
| KR20190107967A (ko) | 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법 | |
| Malbon et al. | Antibodies to Beta-Adrenergic Receptors | |
| CN115028714A (zh) | 一种检测冠状病毒的抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200709 Address after: 430014 A007, 1st floor, building B6, Optical Valley Biological City, 666 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Applicant after: Eason (Wuhan) biomedical Co., Ltd Address before: 430072 Hubei Province, Wuhan city Wuchang District Luojia Hill Applicant before: WUHAN University |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |